Old Articles: <Older 7871-7880 Newer> |
|
The Motley Fool September 14, 2011 Frank Vinluan |
Here's How New Roche Cancer Drug Zelboraf Benefits LabCorp A new Roche cancer drug expected to become a blockbuster could also end up being a boon for laboratory and diagnostics firm LabCorp. |
The Motley Fool September 13, 2011 Brian Orelli |
Drug Launches: It's All About Expectations Optimer jumps on measly sales. |
The Motley Fool September 12, 2011 Jason Moser |
This May Be the Next Great Growth Opportunity Masimo is setting the gold standard in noninvasive patient-monitoring technologies. |
Chemistry World September 12, 2011 Andrew Turley |
Ireland Still Attractive to Pharma Industry The drug industry is still keen to invest in Ireland. |
The Motley Fool September 12, 2011 Frank Vinluan |
GSK Sues to Block Generic BPH Drugs From Mylan, Impax GlaxoSmithKline is taking two drug companies to court claiming that their efforts to launch generic versions of enlarged prostate drugs Avodart and Jalyn infringe on GSK patents. |
The Motley Fool September 12, 2011 Rex Moore |
Warning: MedcoHealth Solutions May Be Hiding Weakness Here are MedcoHealth Solutions' numbers, as well as a bonus look at a few other companies in its industry. |
The Motley Fool September 10, 2011 Rex Moore |
Let's See If Alexion's Growth Is for Real Alexion Pharmaceuticals appears to be in good shape in terms of the intangible assets ratio and tangible book value. |
The Motley Fool September 9, 2011 Evan Niu |
One Medical-Device Stock I Just Bought There have been 8,656 MAKOplasty procedures already performed and the global opportunities are just beginning. |
The Motley Fool September 9, 2011 Brian Orelli |
Firing Squad, It Was Not J&J and Bayer get through their advisory panel with minimal problems. |
The Motley Fool September 9, 2011 Frank Vinluan |
GSK Halts Part of Breast Cancer Trial; Drug Can't Top Herceptin GlaxoSmithKline has halted part of a phase 3 breast cancer clinical study after an independent committee concluded that the GSK drug administered alone is unlikely to work better than a rival cancer drug from Roche. |
<Older 7871-7880 Newer> Return to current articles. |